Arcutis Biotherapeutics, Inc. ARQT ZORYVE Cream0.05 — Product revenue, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s zoryve cream0.05 — product revenue, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s ZORYVE cream0.05 — product revenue, net?
- Arcutis Biotherapeutics, Inc. (ARQT) reported ZORYVE cream0.05 — product revenue, net of $1.36M in Q1 2026.
- What does ZORYVE cream0.05 — product revenue, net mean?
- This metric represents the total net revenue generated from the sale of a specific dermatological product formulation after accounting for returns, discounts, and rebates. It serves as a key indicator of market adoption and commercial traction for the company's therapeutic portfolio within the medical dermatology sector. Tracking this figure allows investors to evaluate the growth trajectory and revenue contribution of a specific product line as it transitions from clinical development to commercialization.